Compare Citius Pharmaceuticals Inc (CTXR) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs PepsiCo, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while PepsiCo, Inc. trades at $125.91 (market cap $174.89B). The key difference: PepsiCo, Inc. is far larger — about 12840.7× Citius Pharmaceuticals Inc's market cap, and PepsiCo, Inc. pays a 4.61% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and PepsiCo, Inc. for 107 Days on average.
| CTXR | PEP | |
|---|---|---|
Market Cap | $13.62M | $174.89B |
Volume | 132,438 | 23,968,864 |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $170.44 |
52-Week Low | $0.48 | $123.64 |
Typical Hold Time | 16 Days | 107 Days |
Enterprise Value | $3.79M | $215.61B |
Dividend Yield | — | 4.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
PepsiCo (PEP) trades at $123.64, down 1.65% on the day, with a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings estimates for four consecutive quarters, with Q3 2026 EPS of $2.34 exceeding expectations. Revenue growth remains steady at $93.93B for 2025, though net income margin declined to 8.77%. Recent news highlights price adjustments for snack products and sponsorship changes.
PepsiCo presents a mixed investment case with strong profitability metrics (ROE 51.59%) and analyst consensus price target of $146.77 (18.7% upside), but faces headwinds from consumer price sensitivity and technical weakness. The company's cash flow stability and dividend payments provide defensive characteristics, though execution risks in North American markets warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
